Related Experiment Videos
A human monoclonal antibody reactive with human prostate.
The Journal of Urology
|October 1, 1984
Summary
Researchers developed a human monoclonal antibody, MHG7, from prostate cancer patient lymph nodes. This antibody targets prostate cancer cells and benign prostatic hypertrophy cells, offering potential for new diagnostics or therapies.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Prostate cancer diagnosis and treatment can be improved with targeted therapies.
- Identifying specific biomarkers on prostate cancer cells is crucial for therapeutic development.
Purpose of the Study:
- To isolate and characterize a human monoclonal antibody reactive against human prostate cells.
- To investigate the potential of using regional lymph node lymphocytes from prostate cancer patients for hybridoma generation.
Main Methods:
- Isolation of lymphocytes from a prostate carcinoma patient's regional draining lymph node.
- Fusion of lymphocytes with murine P3-NS1-Ag4-1 myeloma cells to create hybridomas.
- Screening of hybridoma supernatants for human immunoglobulin production and reactivity against prostate cell lines and tissues using enzyme immunoassay.
Main Results:
- A human immunoglobulin M monoclonal antibody-secreting hybridoma, MHG7, was successfully generated.
- MHG7 demonstrated reactivity with prostate cell lines, prostate carcinoma cells, and benign prostatic hypertrophy cells.
- Antibody reactivity was confirmed on both frozen and paraffin-embedded tissue sections.
Conclusions:
- Regional draining lymph nodes of prostate carcinoma patients are a viable source for generating human hybridomas.
- The MHG7 antibody shows potential as a diagnostic or therapeutic agent targeting prostate cancer and benign prostatic hypertrophy.